新辅助化疗后保乳手术治疗Ⅱ、Ⅲ期乳腺癌的临床观察

Breast conserving treatment after neoadjuvant chemotherapy for Ⅱ and Ⅲ stage breast cancer

目的探讨新辅助化疗后保乳手术治疗Ⅱ、Ⅲ期乳腺癌的可行性。方法对解放军第309医院2003年6月-2008年12月收治的Ⅱ、Ⅲ期乳腺癌经新辅助化疗后接受保乳治疗的46例患者进行随访观察。化疗方案为第1天静脉注射表柔比星60mg/m2,第2天紫杉醇150mg/m2,持续3h静脉滴注,21d为1个疗程,共2～4个疗程。手术方式为象限切除或肿块局部广泛切除联合腋窝淋巴结清除。术后对患者局部复发、远处转移及乳房外形情况进行随访观察。结果新辅助化疗后,术前肿瘤病灶临床完全缓解(CR)9例,部分缓解(PR)37例。术后病理学检查发现,癌细胞均有不同程度的变性、坏死,并伴有细胞间质水肿、纤维增生、炎性细胞浸润,其中病理完全缓解4例,经过58个月的中位随访(8～70个月),局部复发4例(4/46),远处转移3例(3/46),远处转移者中2例死亡。保乳综合治疗(放疗+化疗)结束后1年,对31例患者进行乳房外形评估:优6例、良18例、差7例。结论Ⅱ、Ⅲ期乳腺癌经过新辅助化疗后保乳是可行的,术中规范化切除且术后进行放、化疗及全身综合治疗是保乳治疗成功的关键。

Objective To investigate the feasibility of breast conserving surgery after neoadjuvant chemotherapy for Ⅱ and Ⅲ stage breast cancer.Methods Forty-six patients,suffering from Ⅱ and Ⅲ stage breast cancer admitted to 309 Hospital of PLA from Jun.2003 to Dec.2008,and received breast conserving surgery after neoadjuvant chemotherapy,were followed-up.Chemotherapy protocol included intravenous injection of epirubicin 60mg/m2 on day 1 and continuous intravenous infusion of paclitaxel 150 mg/m2 for 3 hours on day 2.The neoadjuvant chemotherapy was repeated every 21 days for 2-4 cycles.Patients eligible for breast conserving therapy received quadrantectomy or wide excision of tumor plus axillary lymph node resection.Evidence of local recurrence and distant metastasis and breast contour were followed up after surgery.Results After neoadjuvant chemotherapy,9 patients showed complete clinical response（CR）,37 patients showed partial response（PR）.Post-operative pathological examination showed that there were varied degrees of apomorphosis and necrosis of tumor cells,interstitial edema,fibrous hyperplasia,and inflammatory cell infiltration,among them pathological remission was found in 4 cases.The patients were followed up for 8 to 70 months with a mean of 58 months,local recurrence was found in 4 cases distant metastasis was found in 3 patients,and 2 of them died.Assessment of breast contour was carried out in 31 cases 1 year after breast conserving therapy,and excellent results were obtained in 6 cases,good in 18 cases and poor in 7 cases.Conclusions It is safe for patients with Ⅱ-Ⅲ stage breast cancer to receive preoperatively treatment with neoadjuvant chemotherapy.Routine operation,postoperative irradiation and chemotherapy and systemic support are the keys to achieve satisfactory result of breast conserving therapy.